Boston Therapeutics, Inc. signed a Letter of Intent with Dr. Gene D. Morse, Director of the Translational Pharmacology Research Core in the University at Buffalo's Center of Excellence for Bioinformatics and Life Sciences to potentially collaborate on an enrollment program for a preventative clinical trials initiative at several locations in Buffalo, NY and New York City's Chinatown. The purpose of this collaboration initiative is to evaluate the effects of BTI-320 on an individual's HbA1c levels, in particular, who are diabetic and pre-diabetic.
http://ift.tt/1dA8I3o
No comments:
Post a Comment